460. Entecavir versus tenofovir in treatment-na´ve Chronic Hepatitis B patients: THIRD YEAR results of a Real-world Study
Session: Poster Abstract Session: Prevention and Treatment of Viral Infections
Thursday, October 3, 2013
Room: The Moscone Center: Poster Hall C
  • Realist- poster.jpg (701.4 kB)
  • Background:

    Entecavir and tenofovir are oral antivirals effective in the treatment of chronic hepatitis B with high genetic barriers against resistance. In this study, our aim was to evaluate and compare third year efficacies of these agents in a real-life cohort study.


    The Realist study is an observational clinical study enrolling treatment-naive chronic hepatitis B (CHB) patients from 11 different centers. Five hundred patients are enrolled in the study since November 2008. In this study demographic data and treatment responses of patients prescribed entecavir or tenofovir in Realist study were compared.


    One hundred thirty four and 130 patients had been prescribed entecavir and tenofovir, respectively. Baseline HBV DNA and ALT levels, fibrosis scores were similar in both groups. 28% and 35% of patients in the entecavir and tenofovir groups had HBeAg positivity respectively and no significant difference was observed between groups. Mean treatment duration was 32±11months in entecavir and 27±13 months in tenofovir group.There was no significant difference between groups in terms of undetectable HBV DNA levels and normal ALT after 3 year of treatment in HBeAg negative and positive CHB patients (p:0.84). HBeAg seroconversion rate after third year seemed to be higher in entecavir group (38% with Entecavir, 20% with Tenofovir)(p:0.04).


    In real-world clinical practice, entecavir and tenofovir provided comparable efficacy. HBeAg seroconversion rates at third year seemed better with entecavir. However it was also observed that HBeAg seroconversion rates were increasing with time in both groups and were approaching to each other.

    Fehmi Tabak, professor1, Bilgul Mete1, Bahadir Ceylan2, Nail Ozgunes3, Alper Gunduz4, Hayat Karaosmanoglu5, Atahan Cagatay6, Kadir Gokturk7, Levent Erdem8, Funda Kocak9, Ebubekir Senates10, Resat Ozaras1 and Realist Study Group, (1)Infectious Diseases, Cerrahpasa Medical Faculty, Istanbul, Turkey, (2)Infectious Diseases, Bezmi Alem Vakif Gureba Medical Faculty, Istanbul, Turkey, (3)Infectious Diseases, Medeniyet University Goztepe Medical Faculty, Istanbul, Turkey, (4)Infectious Diseases, Sisli Education and Research Hospital, Istanbul, Turkey, (5)Infectious Diseases, Haseki Education and Research Hospital, Istanbul, Turkey, (6)Infectious Diseases, Istanbul Medical Faculty, Istanbul, Turkey, (7)Infectious Diseases, Buyukcekmece Hospital, Istanbul, Turkey, (8)Gastroenterology, Bilim University Medical Faculty, Istanbul, Turkey, (9)Infectious Diseases, Basaksehir Hospitl, Istanbul, Turkey, (10)Gastroenterology, Dicle Medical Faculty, Diyarbakir, Turkey


    F. Tabak, None

    B. Mete, None

    B. Ceylan, None

    N. Ozgunes, None

    A. Gunduz, None

    H. Karaosmanoglu, None

    A. Cagatay, None

    K. Gokturk, None

    L. Erdem, None

    F. Kocak, None

    E. Senates, None

    R. Ozaras, None

    Findings in the abstracts are embargoed until 12:01 a.m. PST, Oct. 2nd with the exception of research findings presented at the IDWeek press conferences.